Hologic, Inc. (NASDAQ:HOLX) has received an average recommendation of “Hold” from the fifteen ratings firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $48.42.
A number of research firms have commented on HOLX. Zacks Investment Research downgraded shares of Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Needham & Company LLC reiterated a “buy” rating and set a $50.00 price objective on shares of Hologic in a research note on Monday, October 2nd. Royal Bank Of Canada reiterated a “hold” rating and set a $42.00 price objective on shares of Hologic in a research note on Friday, September 22nd. BidaskClub downgraded shares of Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Finally, Barclays PLC reiterated an “equal weight” rating and set a $51.00 price objective (down from $53.00) on shares of Hologic in a research note on Wednesday, August 9th.
In other Hologic news, Director Lawrence M. Levy sold 7,139 shares of the stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $39.04, for a total transaction of $278,706.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Karleen Marie Oberton sold 4,704 shares of the stock in a transaction on Monday, July 17th. The stock was sold at an average price of $45.19, for a total transaction of $212,573.76. The disclosure for this sale can be found here. Insiders have sold 18,745 shares of company stock worth $768,189 over the last three months. 0.79% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Hall Laurie J Trustee increased its holdings in shares of Hologic by 10.2% in the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after acquiring an additional 225 shares during the period. Commonwealth Bank of Australia increased its holdings in shares of Hologic by 31.0% in the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after acquiring an additional 600 shares during the period. National Asset Management Inc. acquired a new stake in shares of Hologic in the 2nd quarter worth about $203,000. Beck Mack & Oliver LLC acquired a new stake in shares of Hologic in the 2nd quarter worth about $209,000. Finally, Notis McConarty Edward acquired a new stake in shares of Hologic in the 2nd quarter worth about $213,000. 96.38% of the stock is currently owned by institutional investors and hedge funds.
Shares of Hologic (HOLX) opened at 37.69 on Friday. The company’s 50-day moving average is $37.77 and its 200 day moving average is $42.10. The firm has a market capitalization of $10.57 billion, a price-to-earnings ratio of 14.04 and a beta of 0.91. Hologic has a 52 week low of $35.15 and a 52 week high of $46.80.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. During the same period in the prior year, the firm posted $0.51 EPS. The firm’s revenue was up 12.4% compared to the same quarter last year. Analysts anticipate that Hologic will post $2.01 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Hologic, Inc. (HOLX) Receives Average Recommendation of “Hold” from Brokerages” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://transcriptdaily.com/2017/10/08/hologic-inc-holx-receives-average-recommendation-of-hold-from-brokerages.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.